Efficacy and safety of Chinese herbal medicine versus Lopinavir-Ritonavir in adult patients with coronavirus disease 2019: A non-randomized controlled trial
Nannan Shi(Chinese Academy of Medical Sciences & Peking Union Medical College), Luqi Huang(Shenyang Pharmaceutical University), Jinliang Yang(Chinese Academy of Medical Sciences & Peking Union Medical College), Yongjun Bian(Chinese Academy of Medical Sciences & Peking Union Medical College), Huaxin Shi(Chinese Academy of Medical Sciences & Peking Union Medical College), Wensheng Qi(Chinese Academy of Medical Sciences & Peking Union Medical College), Ming Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Suping Chen(Soochow University), Renbo Chen(Chinese Academy of Medical Sciences & Peking Union Medical College), Wenliang Lv(Chinese Academy of Medical Sciences & Peking Union Medical College), Luxing Leng(Chinese Academy of Medical Sciences & Peking Union Medical College), Haoning Zhu(Chinese Academy of Medical Sciences & Peking Union Medical College), Chunyan Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Yongyue Xian(Chinese Academy of Medical Sciences & Peking Union Medical College), Jiaheng Shi(Chinese Academy of Medical Sciences & Peking Union Medical College), Ryan Zhenqi Zhou(Chinese Academy of Medical Sciences & Peking Union Medical College), Bei Yan(Ningxia Medical University), Jing Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Hao Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Li Li(Risun (China)), Gang Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Bin Li(First Affiliated Hospital of Henan University), Bing Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Dongxu Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Wei Wang(Sun Yat-sen University), Yingying Chen, Jia Liu(Union Hospital), Li Zhang, Xiaodong Cong(Chinese Academy of Medical Sciences & Peking Union Medical College), Jing Guo(State Key Laboratory of Diagnosis and Treatment of Infectious Diseases), Qing Miao(Chinese Academy of Medical Sciences & Peking Union Medical College), Jian Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Bin Liu(China National Nuclear Corporation), Zhan Shi(Chinese Academy of Medical Sciences & Peking Union Medical College), Yibai Xiong(Shanghai University of Traditional Chinese Medicine), Yang Chen(Science for Life Laboratory), Jianxin Jiang(Chinese Academy of Medical Sciences & Peking Union Medical College), Lanping Guo(Chinese Academy of Medical Sciences & Peking Union Medical College), Guoju Dong(Chinese Academy of Medical Sciences & Peking Union Medical College), Yaxin Tian(Chinese Academy of Medical Sciences & Peking Union Medical College), Cheng Lü(Chinese Academy of Medical Sciences & Peking Union Medical College), Lijie Hu(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiaolei Xie(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cited by 59
Related Papers
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
|The Lancet|2020|51.8k
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
|New England Journal of Medicine|2020|5.5k
A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)
|Military Medical Research|2020|2.4k
Targeting PI3K/Akt signal transduction for cancer therapy
|Signal Transduction and Targeted Therapy|2021|1.7k
Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US
|JAMA Internal Medicine|2020|1k